PIK3CA and ovarian carcinoma: In a phase 1 dose-escalation clinical trial, a partial response was observed in a patient with V600E BRAF-mutant melanoma and in a patient with platinum-refractory epithelial ovarian cancer, exhibiting PTEN loss and PIK3CA amplification [57].